Private Placement

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

With zero debt and millions in cash, Atlas Energy is hunting for global oil and gas deals. But can it escape its unique regulatory 'Sandbox' status?

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

With millions of illegal school bus passings a year, new tech like extended stop arms offers a proactive solution. But can it overcome cost and driver apathy?

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

With ex-Sierra Space CEO Tom Vice at the helm, Astrion signals a bold new era, aiming to disrupt the national security and space markets.

Manufacturers are spending millions on ERP systems with poor results. Discover why a 'process-first' approach is becoming critical for survival and growth.

As the Final Four tips off, AI firm TISC hires NCAA champion 'Scooter' Barry to bridge the gap between high-tech analytics and coaching intuition.

With backing from Liberty Mutual, CenterNode aims to inject flexible capital into a market where traditional financing is scarce, accelerating the energy transition.

The data quality firm launches an autonomous system of AI agents designed to monitor, investigate, and act on data, aiming to redefine enterprise AI.

American Ventures publicizes support from 85+ investors, a move to counter a recent fraud lawsuit and an ongoing SEC investigation into its practices.

Dxcover's new AI platform uses infrared light to detect early-stage colorectal, pancreatic, and ovarian cancers from blood with unprecedented sensitivity.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

With $10M from ATEL Ventures, Carbon Upcycling is set to commercialize its breakthrough tech, turning CO2 and industrial waste into green building materials.

IFF targets the booming pet wellness market with PureStrong™, a probiotic built from canine science. Is this the future of dog digestive health?

A $2B facility aims to turn wood waste into clean power while burying carbon, a project that could provide an economic lifeline and reshape the energy grid.

A Utah fintech just landed a massive credit line to disrupt the luxury auto market. Here's how its AI platform is changing the game for car collectors.